SPY334.57+0.24 0.07%
DIA274.62+0.72 0.26%
IXIC11,010.98-97.09 -0.87%

H.C. Wainwright Maintains Buy on BioXcel Therapeutics, Raises Price Target to $30

H.C. Wainwright analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and raises the price target from $25 to $30.

Benzinga · -

H.C. Wainwright analyst Raghuram Selvaraju maintains BioXcel Therapeutics (NASDAQ:BTAI) with a Buy and raises the price target from $25 to $30.